| Autor: |
Sturgess K; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Yankova E; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK., Vijayabaskar MS; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Isobe T; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Rak J; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Kucinski I; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Barile M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Webster NA; Storm Therapeutics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK., Eleftheriou M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK., Hannah R; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Gozdecka M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Vassiliou G; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Rausch O; Storm Therapeutics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK., Wilson NK; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Göttgens B; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK. bg200@cam.ac.uk.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK. bg200@cam.ac.uk., Tzelepis K; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK. kt404@cam.ac.uk.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK. kt404@cam.ac.uk.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK. kt404@cam.ac.uk.; Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK. kt404@cam.ac.uk. |
Full text from SpringerLink